Research Information System
ACTA ONCOLOGICA TURCICA, vol.52, no.3, pp.432-437, 2019 (Peer-Reviewed Journal)
INTRODUCTION: Although the expression of both maspin and GLUT-1 have been shown to increase in manyhuman cancers such as endometrioid carcinoma, their long-term prognostic relevance has not yet beenestablished. The aim of our study is to investigate the overexpression of maspin and GLUT-1 in malignantendometrial tissues, to evaluate its role in the neoplastic progression to an endometrioid carcinoma, to establishprognostic clinical parameters and to predict survival.METHODS: The sample participants comprised of 68 patients with endometrioid adenocarcinoma and 68patients with benign endometrial tissues. The immunostaining pattern for maspin was accepted as nuclear.Nuclear staining of tumoral tissues and normal endometrial tissues were scored according to cell ratios asfollows: negative staining <25%; positive staining 25% - 100%. The linear staining pattern for GLUT-1 wasaccepted as membranous. The percentage of positively stained tumor cells in the tissue samples were semiquantitatively determined with negative staining <5% and positive staining 5% - 100%. The follow-up periodranged from 6 to 60 months with a mean of 53,8 months. Primary end points were determined as all-causemortality.RESULTS: The immunohistochemical expression of GLUT-1 and Maspin were significantly higher in endometrioid carcinoma (p<0.001). There was no statistically significant difference between survival andGLUT-1. Although the survival in patients with maspin staining was lower, statistical significance was notreached (p=0.08). In patients with positive maspin staining, the prognosis is much worse. While GLUT-1 playsan important role in the progression and metastasis of tumors, its activity was not observed in tissues withoverexpressed maspin.DISCUSSION and CONCLUSION: While GLUT-1 is an important immunostaining marker for tumorprogression and metastasis, maspin has been identified to be more effective as a prognostic parameter inendometrioid carcinoma.